Humacyte taps former Schering-Plough exec Carrie Cox as CEO

> Humacyte has named Carrie Cox, formerly of Schering-Plough, as CEO. Humacyte release

>  Pevion Biotech AG has appointed Evert Kueppers as its new CEO, succeeding Thomas Stauffer. Pevion release

> J. Robert Hurley has been named the interim president and CEO of Beckman Coulter following Scott Garrett's announcement that he is resigning as chairman, president and CEO of the company. Story

>  Protalix BioTherapeutics has appointed Tzvi Palash as the company's chief operating officer. Protalix release

> Cubist Pharmaceuticals has announced that Steven Gilman has been promoted to executive VP, R&D and CSO. Cubist release

> Herbert Fritsche, Ph.D., former M.D. Anderson Cancer Center professor and scientist, has joined the Health Discovery Corporation as senior VP and CSO. Health Discovery release

> NeoStem has appointed Ian Zhang as the new president and managing director of NeoStem (China). NeoStem release

> James Szigethy has been named CureMark's director of new product development. CureMark release

> Mark Sawicki has been promoted to VP of business development for Europe at AMRI. Christopher Conway has been promoted to senior director of business development for North American Discovery Services, and Angie Urdanoff has been promoted to senior director, sales operations. AMRI release

> Sofinnova Ventures, a venture capital firm based in Silicon Valley, has announced that Garheng Kong has joined the firm as general partner. He will actively invest in biopharmaceutical companies from the firm's current fund, SVP VII. Sofinnova release

> Regenicin has named Craig Eagle to its board of directors. Dr. Eagle currently serves as VP of strategic alliances and partnerships for the Oncology business unit at Pfizer. Regenicin release

> Fero Industries has named Luis Manuel Ornelas Lopez to its board. Fero release

> Galapagos NV has named Howard Rowe to its board Of directors. Galapagos release

> Nanobiotix has reported that Laurent Condomine has joined its non executive board to help its growth. Nanobiotix release

Stefan Gruenwald has joined Fibrocell Science's scientific advisory board. Fibrocell's release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.